The Second Online Scientific Forum on Novel Vaccine Adjuvants
09: 00 -10: 30, April 19th, 2025 China
Contents of the Meeting
Novel adjuvant is the golden key to develop innovative vaccines, which is the focus of novel human vaccine R&D and veterinary vaccine R&D. Vuroyal always takes the vision of promoting vaccine innovation and global health cooperation, and actively provides professional technical support and the latest cutting-edge trends for domestic vaccine R&D enterprises.
This year's New Vaccine Adjuvants Online Technology Forum will focus on both “human vaccine adjuvants” and “veterinary vaccine adjuvants”.
The human vaccine adjuvants include: QS-21, QS-7, QS-18, etc. The veterinary vaccine adjuvants include: Vet-sap.
Vuroyal will hold the 2nd Online Technology Forum on Novel Vaccine Adjuvants on April 19, 2025 from 09:00am-10:30pm CET, focusing on the research process, clinical application, and related review submissions of saponin adjuvants, and discussing the innovative applications of saponin adjuvants.
We invite vaccine R&D companies, immunology researchers, clinical researchers and others to participate in this forum for training and discussion.
Translated with DeepL.com (free version)
Meeting
09:00 - 09:20 QS-21 Latest News
Speaker: Zoltan Beck, DK Expert, Former Senior Director at Pfizer, Vaccine Research & Development (VRD)
09:20 - 09:40 On the development and application of soap tree saponins as veterinary vaccine adjuvants and feed additives
Speaker: Hernan Cortes, DK Expert, Doctor in Veterinary Medicine, MSc. In Animal Nutrition, PhD in Animal Health
09:40 - 10:00 Focus on the preparation method and application range of veterinary adjuvants (mainly vet-sap, Ultra)
Speaker: Yang Wu, Director and Deputy General Manager, Zhongsheng Edna Biotechnology (Wuhan) Co.
10:00 - 10:30 Q&A
Moderator: Hao Wang, Ph.D., MPA，VuRoyal Chief Executive Officer
Featured Speakers
Zoltan Beck
Former Senior Director at Pfizer, Vaccine Research & Development (VRD)
Broad background in microbiology and immunology, solid knowledge of biophysical characterization of formulations, assay development, adjuvant formulations, and vaccine design.Successfully conducted
and managed scientific studies in development of drug, adjuvants, and vaccine formulations. Participated in several vaccine clinical trials.
Skilled in GLP, GMP, and FDA guidelines. Authored or coauthored about a hundred publications.
Pfizer Senior Director (2020.7 - 2024.11)
U.S. Military HIV Research Program at Walter Reed Army Institute of ResearchSenior Principal Scientist (2005.9 - 2020.7)
Dept. of Medical Microbiology, University of Debrecen Assistant Professor (1996.9 - 2007.12)
Uniformed Services University of the Health Sciences Scientist (2005.1 - 2005.5)
Microbiology and Tumorbiology Center, Karolinska Institute Scientist (1998.6 - 1998.12)
Hernan Cortes
Doctor in Veterinary Medicine
MSc. In Animal Nutrition
PhD in Animal Health
Research focuses on multi-domain applications of saponins from Quillaja saponaria and Yucca schidigera:
Vaccine Enhancement:
Boost vaccine efficacy in poultry and salmon, develop saponin-containing ISCOMs for human RSV vaccines;
Animal Health:
Serve as feed additives to improve disease resistance in poultry, swine, ruminants, fish, and shrimp, preventing SRS in salmon and rotavirus diarrhea in pigs;
Cross-Disciplinary Collaboration:
Partner with Corfo, Saponin Research Center, and Desertking Chile S.A. to explore saponin mechanisms and industrial applications in livestock/aquaculture.
Yang Wu
Director and Deputy General Manager, Zhongsheng Edna Biotechnology (Wuhan) Co.
Ph.D. candidate, Associate Researcher, Senior Engineer, Master's Supervisor at the College of Materials Science, Southwest University. Teaching and Research Faculty Member and Associate Professor at Wuhan Polytechnic University; Visiting Scholar at Teesside University, UK; Ph.D. in Physiology from the University of California, Los Angeles (UCLA); Researcher at the National Institutes of Health (NIH); Currently serves as Director and Deputy General Manager of Zhong Sheng Aidena Biotechnology (Wuhan) Co., Ltd.
Awarded "3551 Innovative Talent"; Technical Expert for the "Belt and Road, Great Wall Project," leading vaccine market expansion in the Middle East and Africa (UAE, Egypt); Published ten sci articles in the past five years, obtained 2 national invention patents, and filed 2 additional patent applications.
Zhong Sheng Aidena Biotechnology (Wuhan) is a company built upon China's leading biotechnological platform system. It has established a verticalized industrial chain spanning adjuvant raw material R&D, production, adjuvant formulation development, and application, with products covering both veterinary and human vaccine fields.
About US
vuRoyal is an FDA-registered, Massachusetts-approved pharmaceutical wholesaler and exporter headquartered in Boston, U.S.A. Since October 2023, vuRoyal has been the official and exclusive partner of DesertKing International (DK) in China. We provide Reference List Drug (RLD), Reference Standard (RS), and Vaccine Adjuvants OS-21, Matrix-M™, QS-7, QS-17, QS-18 and Vet-sap for clinical trials and generic development.
Desert King International (DK) is a manufacturer of human vaccine-quality, GMP-batch saponin-based products that are consistently available. The company is headquartered in the U.S. and has facilities in Chile, Mexico and Italy. We lead the world in innovation in the management, refinement and consistent supply of the highest quality saponin adjuvants and adjuvant precursors. Our product QS-21 is globally recognized as the benchmark for human vaccine quality. The supplied saponins are used in five globally approved vaccines that protect millions of people against COVID-19, malaria, respiratory syncytial virus and shingles. Meanwhile QS-21 is in Phase 3 clinical trials in 26 vaccine candidates in oncology, infectious diseases and Alzheimer's disease. Our commitment to quality and sustainability is trusted worldwide, making us a leader in the health, nutrition, cosmetics, animal health and environmental industries.
